StockNews.AISignal intelligence

Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

Browse signals
TXGBearishEarningsnews
High materiality8/10

Life Science Company 10x Genomics Struggles With Profitability, Analyst Says 2025 Guidance Bakes In NIH Funding Uncertainties

Feb 13, 2025, 3:33 PM EST1 sourcesAI-analyzed
Why it may matterVerify against the original reporting

The EPS loss and lower guidance indicate ongoing challenges. For instance, previous results led to significant analysts' target cuts.

AI summary

What happened, with direct paths to the underlying reporting

TXG reported Q4 EPS loss of $(0.40), missing estimates. Sales decreased 10% year-over-year but beat expectations at $165.02 million. Gross margin rose to 67% due to favorable product mix changes. Guidance for FY 2025 sales is lower than consensus at $610-$630 million. Analysts hold mixed ratings, with two downgrades and one maintained Buy.

  • TXG reported Q4 EPS loss of $(0.40), missing estimates.
  • Sales decreased 10% year-over-year but beat expectations at $165.02 million.
  • Gross margin rose to 67% due to favorable product mix changes.
  • Guidance for FY 2025 sales is lower than consensus at $610-$630 million.
  • Analysts hold mixed ratings, with two downgrades and one maintained Buy.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.

Related signals

More source-backed signals connected by company or event